First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

导出 OA

翻译打印收藏纠错

作者： Stuart L,Goldberg ^[1] ; Jorge E,Cortes ^[2] ; Carlo,Gambacorti-Passerini ^[3] ; Rüdiger,Hehlmann ^[4] ; H Jean,Khoury ^[5] ; Mauricette,Michallet ^[6] ; Ron L,Paquette ^[7] ; Bengt,Simonsson ^[8] ; Teresa,Zyczynski ^[9] ; Aimee,Foreman ^[10] ; Elisabetta,Abruzzese ^[11] ; David,Andorsky ^[12] ; Aart,Beeker ^[13] ; Pascale,Cony-Makhoul ^[14] ; Richard,Hansen ^[15] ; Elza,Lomaia ^[16] ; Eduardo,Olavarria ^[17] ; Michael J,Mauro ^[18]

作者单位： John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. ^[1] The University of Texas, MD Anderson Cancer Center, Houston, Texas. ^[2] University of Milano Bicocca, San Gerardo Hospital, Monza, Italy. ^[3] Universität Heidelberg, Mannheim, Germany. ^[4] Winship Cancer Institute of Emory University, Atlanta, Georgia. ^[5] Centre Hospitalier Lyon-Sud, Pierre-Bénite, France. ^[6] UCLA Medical Center, Los Angeles, California. ^[7] Uppsala Universitet, Uppsala, Sweden. ^[8] Bristol-Myers Squibb, Princeton, New Jersey. ^[9] ICON plc, San Francisco, California. ^[10] S. Eugenio Hospital, Rome, Italy. ^[11] Rocky Mountain Cancer Centers, Boulder, Colorado. ^[12] Spaarne Hospital, Hoofddorp, The Netherlands. ^[13] Centre Hospitalier Annecy-Genevois, Pringy, France. ^[14] IDGGQ, Institut für med, Kaiserslautern, Germany. ^[15] Federal Almazov North-West Medical Research Centre, St Petersburg, Russia. ^[16] Hammersmith Hospital, Imperial College London, London, United Kingdom. ^[17] Memorial Sloan-Kettering Cancer Center, New York City, New York. ^[18]